<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01096160</url>
  </required_header>
  <id_info>
    <org_study_id>8266-002</org_study_id>
    <secondary_id>2010_522</secondary_id>
    <nct_id>NCT01096160</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 (8266-002)(COMPLETED)</brief_title>
  <official_title>A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of MK8266.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability of multiple oral doses of MK8266 measured by number of clinical and laboratory adverse experiences</measure>
    <time_frame>up to 24 hours post last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline and 24 hours post dose on dosing Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Aortic Augmentation index (AIx) following multiple oral doses of MK8266</measure>
    <time_frame>Dosing day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cyclic Guanosine Monophosphate (cGMP)</measure>
    <time_frame>Baseline and 24 hours post dose on dosing Day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Panel A - 1 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK8266 1 mg once daily or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B - 2 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK8266 2mg once daily or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C - 4 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK8266 4 mg once daily or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel D - 4 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK8266 4 mg twice daily or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel E - 4 mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK8266 4 mg three times daily or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK8226 1 mg QD</intervention_name>
    <description>MK8266 1 mg once daily for 10 days, as oral capsule</description>
    <arm_group_label>Panel A - 1 mg QD</arm_group_label>
    <other_name>MK8266</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK8266 2 mg QD</intervention_name>
    <description>MK8266 2 mg once daily for 10 days, as oral capsule</description>
    <arm_group_label>Panel B - 2 mg QD</arm_group_label>
    <other_name>MK8266</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK8266 4 mg QD</intervention_name>
    <description>MK8266 4 mg once daily for 10 days, as oral capsule</description>
    <arm_group_label>Panel C - 4 mg QD</arm_group_label>
    <other_name>MK8266</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK8266 4 mg BID</intervention_name>
    <description>MK8266 4 mg twice daily for 10 days, as oral capsule</description>
    <arm_group_label>Panel D - 4 mg BID</arm_group_label>
    <other_name>MK8266</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK8266 4 mg TID</intervention_name>
    <description>MK8266 4 mg three times daily for 10 days, as oral capsule</description>
    <arm_group_label>Panel E - 4 mg TID</arm_group_label>
    <other_name>MK8266</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Placebo oral capsule (once, twice or three times daily) for 10 days</description>
    <arm_group_label>Panel A - 1 mg QD</arm_group_label>
    <arm_group_label>Panel B - 2 mg QD</arm_group_label>
    <arm_group_label>Panel C - 4 mg QD</arm_group_label>
    <arm_group_label>Panel D - 4 mg BID</arm_group_label>
    <arm_group_label>Panel E - 4 mg TID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male with essential hypertension (high blood pressure)

          -  Subject is in good general health (with the exception of hypertension)

          -  Subject is a non-smoker

        Exclusion Criteria:

          -  Subject has a history of stroke, chronic seizure, or major neurological disease

          -  Subject has a functional disability that can interfere with rising from a seated
             position to the standing position

          -  Subject has any history of a bleeding or clotting disorder

          -  Subject has a history of cancer

          -  Subject is unable to refrain from or anticipates the use of any prescription or
             non-prescription medication

          -  Subject consumes excessive amounts of alcohol or caffeinated beverages daily
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>58 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 21, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

